CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with leading research institutions to establish FDA-regulated clinical trials, requiring CBR processed cord blood, for conditions that have no cure today. This is only made possible by CBR's relentless pursuit of product quality. That's why more families choose CBR. We have stored over 500,000 cord blood and cord tissue stem cell units and are the #1 recommended cord blood company by OB/GYNs and expecting parents.
Ultimate use of newborn stem cells will be determined by the treating physician who will consider if they are applicable for the condition and should come from the patient or a suitable donor (siblings of the same biological parents have a 25% chance of being a perfect match and a 50% chance of being a partial match; biological parents will always be a partial match). There is no guarantee that treatments being studied in the laboratory, clinical trials, or other experimental treatments (including regenerative medicine applications) will be available in the future.
For references, click here.
Copyright © 1995 - 2018 CBR Systems, Inc. All rights reserved.